SRI International Recipient of $56.9M from the NIAID
Company will support development of drugs and antibodies for avian flu, SARS, West Nile virus, and other infectious conditions.
SRI International has been awarded a $56.9-million contract from the NIAID to provide preclinical services for the development of drugs and antibodies for anti-infective therapeutics.
SRI will support the development of treatments for avian flu, SARS, West Nile virus, hepatitis, and biodefense pathogens and toxins for five years. The company will perform medicinal chemistry, custom drug synthesis, formulation, analytical chemistry, clinical manufacturing, microbiology and virology screening, pharmacokinetics, safety testing, and preparation of IND applications to the FDA.